The growing epidemic of HPV-positive oropharyngeal carcinoma: A clinical review for primary care providers

Journal of the American Board of Family Medicine

Volumn 28, Issue 4, 2015, Pages 498-503

  Moore, Kevin A ^a   Mehta, Vikas ^a  

^a Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

Cancer; Epidemiology; Head and neck cancer; Human papillomavirus; Oropharyngeal cancer; Otolaryngology

Indexed keywords

WART VIRUS VACCINE;

CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; EPIDEMIC; EVALUATION STUDY; HEALTH CARE PERSONNEL; HUMAN; MEDICAL SPECIALIST; MORBIDITY; MORTALITY; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PATIENT REFERRAL; PREVALENCE; PRIMARY MEDICAL CARE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; TREATMENT RESPONSE; VACCINATION; COMPLICATION; EARLY CANCER DIAGNOSIS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PHYSICIAN ATTITUDE; PRIMARY HEALTH CARE; TRANSMISSION; UNITED STATES; VIROLOGY;

EARLY DETECTION OF CANCER; HUMANS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PHYSICIAN'S ROLE; PREVALENCE; PRIMARY HEALTH CARE; RISK FACTORS; UNITED STATES;

EID: 84937131136     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2015.04.140301     Document Type: Review

References (20)

1. Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharygeal cancer. Oral Oncol 2014;50:380-6.
2. Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer - systematic review and meta-analysis of trends by time and region. Head Neck 2013;35:747-55.
3. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-301.
4. McIlwain WR, Sood AJ, Nguyen SA, Day TA. Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 2014;140:441-7.
5. O'Rorke MA, Ellison MV, Murray LJ, Moran M, James J, Anderson LA. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol 2012;48:1191-201.
6. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9.
7. Zaravinos A. An updated overview of HPV-associated head and neck carcinomas. Oncotarget 2014;5:3956-69.
8. Gillison ML, Broutian T, Pickard RKL, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012;307:693-703.
9. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008;100:407-20.
10. D'Souza G, Cullen K, Bowie J, Thorpe R, Fakhry C. Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS One 2014;9:e86023.
11. Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clinl Oncol 2012;30:2102-11.
12. Howard JD, Chung CH. Biology of human papillomavirus-related oropharyngeal cancer. Semin Radiat Oncol 2012;22:187-93.
13. Rogers SN, Vedpathak SV, Lowe D. Reasons for delayed presentation in oral and oropharyngeal cancer: the patients perspective. Br J Oral Maxillofac Surg 2011;49:349-53.
14. Jakscha et al. The clinical impact of p16 status in fine-needle aspirates of cervical lymph node metastasis of head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol 2013;270:661-7.
15. Corey AS, Hudgins PA. Radiographic imaging of human papillomavirus related carcinomas of the oropharynx. Head Neck Pathol 2012;6:S25-40.
16. Broglie MA, Soltermann A, Haile SR, et al. Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16 positivity. Laryngoscope 2013;123:164-70.
17. Pfister DG, Ang KK, Brizel DM, et al; National Comprehensive Cancer Network. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11:917-23.
18. Herrero R, Quint W, Hildesheim A. Reduced prevalence of oral human papillomavirus 4 years after bivalent hpv vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013;8:e68329.
19. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of Human Papillomavirus Vaccination in the United States. Emerging Infectious Diseases 2008; 14:244-251.
20. Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006;31:72-9.